Enrique Conterno, FibroGen
As it awaits pivotal review of lead drug, FibroGen bolsters its early pipeline with licensing deal for galectin program
FibroGen’s long-awaited review for anemia med roxadustat is just weeks away, and there’s good reason to believe the outcome won’t swing in its favor after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
